Research ArticleArticle
Optimized Pyridazinone Nutrient Channel Inhibitors Are Potent and Specific Antimalarial Leads
Michelle M. Butler, Samanthi L. Waidyarachchi, Jinfeng Shao, Son T. Nguyen, Xiaoyuan Ding, Steven C. Cardinale, Lucas R. Morin, Steven M. Kwasny, Mai Ito, Jeanine Gezelle, María B. Jiménez-Díaz, Iñigo Angulo-Barturen, Robert T. Jacobs, Jeremy N. Burrows, Zachary D. Aron, Terry L. Bowlin and Sanjay A. Desai
Molecular Pharmacology September 2022, 102 (3) 172-182; DOI: https://doi.org/10.1124/molpharm.122.000549
Michelle M. Butler
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)
Samanthi L. Waidyarachchi
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)
Jinfeng Shao
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)
Son T. Nguyen
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)
Xiaoyuan Ding
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)
Steven C. Cardinale
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)
Lucas R. Morin
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)
Steven M. Kwasny
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)
Mai Ito
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)
Jeanine Gezelle
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)
María B. Jiménez-Díaz
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)
Iñigo Angulo-Barturen
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)
Robert T. Jacobs
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)
Jeremy N. Burrows
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)
Zachary D. Aron
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)
Terry L. Bowlin
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)
Sanjay A. Desai
Microbiotix, Inc., One Innovation Dr., Worcester, Massachusetts (M.M.B., S.L.W., S.T.N., X.D., S.C.C., L.R.M., S.M.K., Z.D.A., T.L.B.); Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Rockville, Maryland (J.S., M.I., J.G., S.A.D.); The Art of Discovery, SL, Biscay, Basque Country, Spain (M.B.J.-D., I.A.-B.); and Medicines for Malaria Venture, Geneva, Switzerland (R.T.J., J.N.B.)

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
Pyridazinone Antimalarial Leads
Michelle M. Butler, Samanthi L. Waidyarachchi, Jinfeng Shao, Son T. Nguyen, Xiaoyuan Ding, Steven C. Cardinale, Lucas R. Morin, Steven M. Kwasny, Mai Ito, Jeanine Gezelle, María B. Jiménez-Díaz, Iñigo Angulo-Barturen, Robert T. Jacobs, Jeremy N. Burrows, Zachary D. Aron, Terry L. Bowlin and Sanjay A. Desai
Molecular Pharmacology September 1, 2022, 102 (3) 172-182; DOI: https://doi.org/10.1124/molpharm.122.000549
Research ArticleArticle
Pyridazinone Antimalarial Leads
Michelle M. Butler, Samanthi L. Waidyarachchi, Jinfeng Shao, Son T. Nguyen, Xiaoyuan Ding, Steven C. Cardinale, Lucas R. Morin, Steven M. Kwasny, Mai Ito, Jeanine Gezelle, María B. Jiménez-Díaz, Iñigo Angulo-Barturen, Robert T. Jacobs, Jeremy N. Burrows, Zachary D. Aron, Terry L. Bowlin and Sanjay A. Desai
Molecular Pharmacology September 1, 2022, 102 (3) 172-182; DOI: https://doi.org/10.1124/molpharm.122.000549
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement